163 related articles for article (PubMed ID: 24116905)
1. New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer.
Zarogoulidis P; Yarmus L; Zarogoulidis K
Ther Deliv; 2013 Oct; 4(10):1221-3. PubMed ID: 24116905
[No Abstract] [Full Text] [Related]
2. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Thatcher N
Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
[TBL] [Abstract][Full Text] [Related]
3. Doubling down with inhibitors of Notch and Hedgehog signaling pathways.
Weiss GJ
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S409-10. PubMed ID: 23160337
[No Abstract] [Full Text] [Related]
4. Targeted therapy of non-small-cell lung carcinoma.
Tiwari D; Brodie SA; Brandes JC
Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
[TBL] [Abstract][Full Text] [Related]
5. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Bayliss TJ; Smith JT; Schuster M; Dragnev KH; Rigas JR
Expert Opin Biol Ther; 2011 Dec; 11(12):1663-8. PubMed ID: 21995322
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
[TBL] [Abstract][Full Text] [Related]
7. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.
Somaiah N; Simon NG; Simon GR
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S342-68. PubMed ID: 23160320
[No Abstract] [Full Text] [Related]
8. Identification of 2,3,6-trisubstituted quinoxaline derivatives as a Wnt2/β-catenin pathway inhibitor in non-small-cell lung cancer cell lines.
Lee SB; Park YI; Dong MS; Gong YD
Bioorg Med Chem Lett; 2010 Oct; 20(19):5900-4. PubMed ID: 20729080
[TBL] [Abstract][Full Text] [Related]
9. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.
Taniguchi K; Karin M
Semin Immunol; 2014 Feb; 26(1):54-74. PubMed ID: 24552665
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for non-small cell lung cancer.
Jett JR; Carr LL
Am J Respir Crit Care Med; 2013 Oct; 188(8):907-12. PubMed ID: 23721055
[TBL] [Abstract][Full Text] [Related]
11. Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout.
Favoni RE; Alama A
Drug Discov Today; 2013 Jan; 18(1-2):11-24. PubMed ID: 22885521
[TBL] [Abstract][Full Text] [Related]
12. Gene of the month: Interleukin 6 (IL-6).
Ataie-Kachoie P; Pourgholami MH; Richardson DR; Morris DL
J Clin Pathol; 2014 Nov; 67(11):932-7. PubMed ID: 25031389
[TBL] [Abstract][Full Text] [Related]
13. [Advances in combined modality therapy for patients with operable non-small cell lung cancer].
He J
Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):1-5. PubMed ID: 22490846
[No Abstract] [Full Text] [Related]
14. Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.
Massarelli E; Papadimitrakopoulou VA
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S379-82. PubMed ID: 23160325
[No Abstract] [Full Text] [Related]
15. Phosphatidylinositol-3-kinase pathway.
Reckamp KL
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S383-4. PubMed ID: 23160326
[No Abstract] [Full Text] [Related]
16. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer.
Haura EB; Livingston S; Coppola D
Clin Lung Cancer; 2006 Jan; 7(4):273-5. PubMed ID: 16512982
[TBL] [Abstract][Full Text] [Related]
17. Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy.
Liu Y; Lin J
Future Oncol; 2011 Feb; 7(2):161-4. PubMed ID: 21345134
[No Abstract] [Full Text] [Related]
18. More Benefits for Checkpoint Inhibitors in NSCLC.
Cancer Discov; 2015 Dec; 5(12):OF2. PubMed ID: 26511141
[TBL] [Abstract][Full Text] [Related]
19. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?
Booton R; Blackhall F; Kerr K
Thorax; 2011 Apr; 66(4):273-5. PubMed ID: 21345972
[No Abstract] [Full Text] [Related]
20. Targeted lung cancer therapies.
Farmer G
Nat Rev Drug Discov; 2004 Jul; 3(7):547-8. PubMed ID: 15272497
[No Abstract] [Full Text] [Related]
[Next] [New Search]
